Chen et al. (2021[15]) conducted a meta-analysis of 91 clinical trials to assess the effectiveness of PD-1/PD-L1 inhibitors in various clinical scenarios, quantifying overall response rate, time to response, and duration of response across different cancers, treatment lines, drug combinations, and regimens. Here, CD274 is linked to cancer.